TRIAL INFORMATION
Sponsor:NovaCell Therapeutics
Therapeutic Area:Oncology
Phase:PHASE III
Indication:Non-Small Cell Lung Cancer (Stage IIIB/IV)
Target Enrollment:45 patients
Est. Duration:30 months
SITE INFORMATION
Site:MedPoint Clinical Research - Nashville
Principal Investigator:Dr. Sarah Chen, MD, PhD
Total FTE Capacity:12
Available FTE:1.8
Active Trials:6
Completed Trials:18
Pool Analysis
FTE Analysis
Financial
Risk Assessment
Recommendation
Patient Pool Adequacy Analysis
Assessing whether the available patient pool can support target enrollment
A pool adequacy ratio of 2.5x or higher indicates comfortable capacity for successful enrollment.
TOTAL POOL
2,500
AVAILABLE
2,080
420 allocated
REQUIRED
45
ADEQUACY RATIO
46.2x
Pool Utilization
Current Allocation16.8%
If This Trial Accepted18.6%
Pool is Sufficient
Available pool is 46.2x the target enrollment, providing a comfortable buffer for recruitment.
Pool Adequacy Score100 / 100